Valence8 US’s Janux Therapeutics JANX Stock Holding History

Valence8 US’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,300	Closed	-$104K	–	38
2024 Q3	$104K	Buy	+2,300	New	+$100K	0.04%	52

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Valence8 US's JANX Position: Q4 2024 in Review

Valence8 US sold out of Janux Therapeutics (JANX) in Q4 2024, closing a stake of 7,857 shares — an estimated $357K sold.

Valence8 US first reported a position in JANX in Q3 2024 and held it in 1 quarter. The position peaked at $357K in Q3 2024. 216 funds tracked by Wall St. Rank hold JANX as of Q4 2024.

Valence8 US reported no remaining Janux Therapeutics position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 7,857 Janux Therapeutics shares in Q4 2024, an estimated $357K.
Valence8 US first reported a position in Janux Therapeutics in Q3 2024 and held it in 1 quarter.
Valence8 US's Janux Therapeutics position peaked at $357K in Q3 2024.
216 funds tracked by Wall St. Rank held Janux Therapeutics as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.